There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants.
The other six biotechs we highlight have major clinical trial readouts set for 2020, which could prove transformative for these companies in the hunt for additional NASH therapies. Big drugmakers have faced years of costly failures in the fight to come up with treatments for the silent liver disease known as NASH."It's been such a graveyard of failures because the biology is so poorly understood," Baird analyst Brian Skorney recently told Business Insider.
Note: This list doesn't include big pharma companies with notable NASH readouts set for this year, such as Novo Nordisk's test of a diabetes drug against the liver disease. There are also some significant NASH biotechs set for a quiet 2020, such as Madrigal Pharmaceuticals, which is set to reveal data on how well its treatment works in the second part of next year.solidified its pole position in the race to market in 2019, as potential competition faltered in clinical testing.
The company said it hasn't yet seen the data, and the delay will allow Genfit to "incorporate the latest FDA insights expected by the end of March." There will be much more data to come. The company expects to provide results from a study specifically focused on the most severe NASH patients before the end of June.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »
ソース: CNN - 🏆 4. / 95 続きを読む »
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »